248 related articles for article (PubMed ID: 21197560)
1. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.
Xu B; Niu X; Zhang X; Tao J; Wu D; Wang Z; Li P; Zhang W; Wu H; Feng N; Wang Z; Hua L; Wang X
Mol Cell Biochem; 2011 Apr; 350(1-2):207-13. PubMed ID: 21197560
[TBL] [Abstract][Full Text] [Related]
2. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.
Yu J; Lu Y; Cui D; Li E; Zhu Y; Zhao Y; Zhao F; Xia S
Oncol Rep; 2014 Feb; 31(2):910-8. PubMed ID: 24317363
[TBL] [Abstract][Full Text] [Related]
3. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
Liu Y; Zhang M; Qian J; Bao M; Meng X; Zhang S; Zhang L; Zhao R; Li S; Cao Q; Li P; Ju X; Lu Q; Li J; Shao P; Qin C; Yin C
DNA Cell Biol; 2015 Jun; 34(6):429-36. PubMed ID: 25811077
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.
Guo J; Feng Z; Huang Z; Wang H; Lu W
Mol Cells; 2014 Sep; 37(9):664-71. PubMed ID: 25234467
[TBL] [Abstract][Full Text] [Related]
5. MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
Yang F; Luo LJ; Zhang L; Wang DD; Yang SJ; Ding L; Li J; Chen D; Ma R; Wu JZ; Tang JH
Gene; 2017 Feb; 600():21-28. PubMed ID: 27913185
[TBL] [Abstract][Full Text] [Related]
6. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
7. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
8. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
[TBL] [Abstract][Full Text] [Related]
10. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
Siu MK; Abou-Kheir W; Yin JJ; Chang YS; Barrett B; Suau F; Casey O; Chen WY; Fang L; Hynes P; Hsieh YY; Liu YN; Huang J; Kelly K
Oncotarget; 2014 Jun; 5(11):3770-84. PubMed ID: 25004126
[TBL] [Abstract][Full Text] [Related]
11. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
14. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
15. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
16. microRNA-27a functions as a tumor suppressor in esophageal squamous cell carcinoma by targeting KRAS.
Zhu L; Wang Z; Fan Q; Wang R; Sun Y
Oncol Rep; 2014 Jan; 31(1):280-6. PubMed ID: 24154848
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.
Fu X; Zhang W; Su Y; Lu L; Wang D; Wang H
Prostate; 2016 May; 76(6):543-51. PubMed ID: 26771762
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
19. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
[TBL] [Abstract][Full Text] [Related]
20. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
Shi GH; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Xiao WJ; Ma CG
Acta Pharmacol Sin; 2010 Jul; 31(7):867-73. PubMed ID: 20581857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
